CD276 and neoplasm: CD276 is broadly expressed on tumor cells and with relatively limited expression in normal tissues, making it an ideal candidate for antibody-based therapy, particularly Fc-engineered antibodies designed to enhance NK cell-mediated tumor cytotoxicity (42, 43).